Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? - Wikidata - awgldk - TriplyDB

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

http://www.wikidata.org/entity/Q25256872

about

Diversity-generating retroelements Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1 Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.Antiretroviral drug resistance in human immunodeficiency virus type 2.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Diversity-generating Retroelements in Phage and Bacterial Genomes.MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.Novel inhibitors of human immunodeficiency virus type 2 infectivity.Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.AZT-resistant foamy virus.Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.AZT resistance of simian foamy virus reverse transcriptase is based on the excision of AZTMP in the presence of ATP.Antiretroviral drug resistance in HIV-2: three amino acid changes are sufficient for classwide nucleoside analogue resistance.Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.HIV-1 with HBV-associated Q151M substitution in RT becomes highly susceptible to entecavir: structural insights into HBV-RT inhibition by entecavir.Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.

P2860

Q24656393-30E04891-5FD2-4661-9F8E-AC47B50F2092 Q28477614-ABB3AF28-A382-4C62-99BC-00EA4CC77553 Q33743954-851FE0A0-DAD7-45E1-804C-9A1C8C6187EC Q33963958-E3901216-D100-4E8D-A250-71833E2F52BB Q34992731-BA33C3A5-E760-4665-8457-595422A96E7B Q35633587-D5EA15F1-4BA6-4D49-B238-987379402414 Q35857522-2CD9D917-01D5-4847-B7F1-AF79F5924E26 Q35943486-087D5AE9-3F06-4CE5-8256-B5EE92FCB502 Q36202747-2EABE466-9D9E-4867-A1F5-5F1695C3DBEA Q36290647-44A326B5-4C55-41FE-990D-B4F52978B3A5 Q36290768-98667764-7819-41F9-A9F6-22DDE5B611B6 Q36422635-92261C43-E3C1-455D-828E-0AE18F772F63 Q37072022-AF8651C0-E375-4D24-87CA-87F1BA581193 Q37083896-DEEA873D-9BE7-4DA3-9B8D-41ADCAB60022 Q37307096-23284640-FE47-475E-B779-A97432CA7EAA Q37432131-C81A8C03-5D59-42FF-8A47-1BC6D35DC7A0 Q37496287-3B1760BF-5393-4E06-A20B-37C40CC5A98E Q37859395-91A7D4E7-DF03-4862-B53B-35C49254DC39 Q38535893-9E86EA7D-10C4-48B3-B9D9-8562E073D5BC Q38755690-6281CEC1-2A9E-4004-9F31-F0DD84EF0389 Q38967949-A199BA1E-7B3A-48DF-9AB5-764FA5EE32AF Q39142877-61BA3FBA-FE16-43B1-A546-BB8DA8DA75D8 Q39912641-1DD8B6D8-2B70-4A48-9B9D-E5B82AD59948 Q40074663-A251720B-0088-42DB-A3AB-66E3A483B378 Q40432241-7F5F0FC5-7116-4648-BDC5-E31261017DC3 Q41857872-AD11BA42-DFEC-4D23-8350-F86C25D1F690 Q41878118-DC39443F-E520-4607-AD79-F7A4515C96C4 Q43070074-2BE00FA1-1B03-4F9D-8BED-431FE0F2EBAA Q44990505-819CE097-0DED-4977-B0FE-F0166100CD91 Q47548606-A281C3AA-3351-4D35-9F82-8BBAD1049DE4 Q47560712-A080944B-2C18-4219-889A-17647A6C2367

P2860

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

http://www.wikidata.org/entity/Q25256872

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@ast

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@en

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@nl

type

label

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@ast

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@en

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@nl

prefLabel

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@ast

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@en

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@nl

P1433

Q25256872-DBBAEDCE-746B-4852-ACEC-746E9D0D5EC2

P1476

Q25256872-F2DA4963-544B-414F-8C8F-0AC5D545FB07

P2093

Q25256872-6C5C6DAC-D847-4F13-BF3D-0222948EE0D1

Q25256872-8EA47A56-E8C4-40FF-9C60-FD650E3D51C4

Q25256872-B967C4F9-F44D-44C4-8615-93116842315F

Q25256872-C30322A4-77E5-4256-AE47-E629EB30D88F

P2860

Q25256872-02D59199-396B-4815-880F-464DFCBD5818

Q25256872-163378C4-526F-4D43-B5D9-FF5485265A9F

Q25256872-1A4B0434-E583-4068-BA1D-F26F2CE34BFC

Q25256872-224D7A4D-97BC-4E2C-BE0C-9F630812BFF4

Q25256872-33CB953E-8D1A-4D32-9979-65C3748A07BF

Q25256872-40C368BB-21D9-4103-9ECF-690E6A683D06

Q25256872-4283C5F1-4F0A-42CA-B3D2-11FA7EB4FABC

Q25256872-55E493CD-AD3B-4CAC-B389-5650A91E3BAE

Q25256872-5FBB644F-751D-4929-B485-BCF011A65E8B

Q25256872-686E5AD8-10B3-48B5-97C3-C6F63677E2E8

P304

Q25256872-6B252CDD-FE64-4CD8-AFCE-3582D721A395

P31

Q25256872-475FE885-6AAF-4CCE-878C-7C0ECF7E0E08

P356

Q25256872-70EAFD83-61CE-47FF-91FA-35BE45755E44

P407

Q25256872-DE1AEE09-4929-4A7B-822A-276598A1741C

P433

Q25256872-0651A1DF-A451-4691-95B7-8E36A4FEF194

P478

Q25256872-96201BE1-F1CB-404E-9855-4BBB1A1BCC63

P50

Q25256872-8D1F63EC-E9D8-4025-8A9A-F38ECFAD1618

Q25256872-CB8C3BEF-44F7-419C-B8EC-6AD35E2685A2

P577

Q25256872-C8D2AABA-2251-4861-B4B1-21A7783599B4

P5875

Q25256872-AA5B2A44-9D35-47BC-BB24-4406FBAE8A2C

P698

Q25256872-50F416C6-3B0C-4BF7-9B89-9A166F753900

P921

Q25256872-6F5AE6E3-DA10-4793-9788-58CC7C438960

P932

Q25256872-B7EF20FB-3444-4763-B46E-85013C88962C

P356

JOURNAL.PPAT.0020010

P1433

P1476

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

@en

P2093

Eddy Arnold

http://www.w3.org/2001/XMLSchema#string

Patrick K Clark

http://www.w3.org/2001/XMLSchema#string

Paul L Boyer

http://www.w3.org/2001/XMLSchema#string

Stefan G Sarafianos

http://www.w3.org/2001/XMLSchema#string

P2860

Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.

Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy

Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism

Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1

Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an In vitro competitive HIV-1 replication assay

Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy

Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants.

The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1

Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.

P304

e10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.0020010

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Stephen H. Hughes

P577

2006-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7292196

http://www.w3.org/2001/XMLSchema#string

P698

16485036

http://www.w3.org/2001/XMLSchema#string

P921

P932

1364504

http://www.w3.org/2001/XMLSchema#string